{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T03:20:35Z","timestamp":1791688835167,"version":"4.3.4"},"reference-count":191,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T00:00:00Z","timestamp":1610064000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T00:00:00Z","timestamp":1610064000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s00415-020-10362-z","type":"journal-article","created":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T05:08:17Z","timestamp":1610082497000},"page":"159-183","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":171,"title":["Rituximab for the treatment of multiple sclerosis: a review"],"prefix":"10.1007","volume":"269","author":[{"given":"Clara Grazia","family":"Chisari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Sgarlata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiano","family":"Arena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Toscano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Luca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6923-0846","authenticated-orcid":false,"given":"Francesco","family":"Patti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,8]]},"reference":[{"issue":"1","key":"10362_CR1","doi-asserted-by":"publisher","first-page":"120","DOI":"10.3390\/jcm8010120","volume":"8","author":"BM Segal","year":"2019","unstructured":"Segal BM (2019) The diversity of Encephalitogenic CD4+ T cells in multiple sclerosis and its animal models. J Clin Med 8(1):120. https:\/\/doi.org\/10.3390\/jcm8010120","journal-title":"J Clin Med"},{"issue":"9","key":"10362_CR2","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/nri3871","volume":"15","author":"CA Dendrou","year":"2015","unstructured":"Dendrou CA, Fugger L, Friese MA (2015) Immunopathology of multiple sclerosis. Nat Rev Immunol 15(9):545\u2013558. https:\/\/doi.org\/10.1038\/nri3871","journal-title":"Nat Rev Immunol"},{"issue":"9","key":"10362_CR3","doi-asserted-by":"publisher","first-page":"e00362","DOI":"10.1002\/brb3.362","volume":"5","author":"N Garg","year":"2015","unstructured":"Garg N, Smith TW (2015) An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis. Brain Behav 5(9):e00362. https:\/\/doi.org\/10.1002\/brb3.362","journal-title":"Brain Behav"},{"issue":"1","key":"10362_CR4","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1080\/08916934.2017.1281914","volume":"50","author":"H Wekerle","year":"2017","unstructured":"Wekerle H (2017) B cells in multiple sclerosis. Autoimmunity 50(1):57\u201360. https:\/\/doi.org\/10.1080\/08916934.2017.1281914","journal-title":"Autoimmunity"},{"issue":"11","key":"10362_CR5","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/nrneurol.2012.203","volume":"8","author":"M Krumbholz","year":"2012","unstructured":"Krumbholz M, Derfuss T, Hohlfeld R, Meinl E (2012) B cells and antibodies in multiple sclerosis pathogenesis and therapy. Nat Rev Neurol 8(11):613\u2013623. https:\/\/doi.org\/10.1038\/nrneurol.2012.203","journal-title":"Nat Rev Neurol"},{"issue":"7","key":"10362_CR6","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/s41590-018-0135-x","volume":"19","author":"R Li","year":"2018","unstructured":"Li R, Patterson KR, Bar-Or A (2018) Reassessing B cell contributions in multiple sclerosis. Nat Immunol 19(7):696\u2013707. https:\/\/doi.org\/10.1038\/s41590-018-0135-x","journal-title":"Nat Immunol"},{"key":"10362_CR7","doi-asserted-by":"publisher","first-page":"101416","DOI":"10.1016\/j.msard.2019.101416","volume":"36","author":"P Wanleenuwat","year":"2019","unstructured":"Wanleenuwat P, Iwanowski P (2019) Role of B cells and antibodies in multiple sclerosis. Mult Scler Relat Disord 36:101416. https:\/\/doi.org\/10.1016\/j.msard.2019.101416","journal-title":"Mult Scler Relat Disord"},{"issue":"1\u20132","key":"10362_CR8","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.jneuroim.2012.02.015","volume":"246","author":"RP Lisak","year":"2012","unstructured":"Lisak RP, Benjamins JA, Nedelkoska L, Barger JL, Ragheb S, Fan B, Ouamara N, Johnson TA, Rajasekharan S, Bar-Or A (2012) Secretory products of multiple sclerosis B cells are cytotoxic to oligodendroglia in vitro. J Neuroimmunol 246(1\u20132):85\u201395. https:\/\/doi.org\/10.1016\/j.jneuroim.2012.02.015","journal-title":"J Neuroimmunol"},{"key":"10362_CR9","doi-asserted-by":"publisher","first-page":"3116","DOI":"10.3389\/fimmu.2018.03116","volume":"9","author":"H Lassmann","year":"2018","unstructured":"Lassmann H (2018) Pathogenic Mechanisms Associated With Different Clinical Courses of Multiple Sclerosis. Front Immunol 9:3116. https:\/\/doi.org\/10.3389\/fimmu.2018.03116","journal-title":"Front Immunol"},{"issue":"1","key":"10362_CR10","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.cell.2018.08.011","volume":"175","author":"I Jelcic","year":"2018","unstructured":"Jelcic I, Al Nimer F, Wang J, Lentsch V, Planas R, Jelcic I, Madjovski A, Ruhrmann S, Faigle W, Frauenknecht K, Pinilla C, Santos R, Hammer C, Ortiz Y, Opitz L, Gronlund H, Rogler G, Boyman O, Reynolds R, Lutterotti A, Khademi M, Olsson T, Piehl F, Sospedra M, Martin R (2018) Memory B cells activate brain-homing autoreactive CD4(+) T cells in multiple sclerosis. Cell 175(1):85\u2013100. https:\/\/doi.org\/10.1016\/j.cell.2018.08.011","journal-title":"Cell"},{"issue":"Pt 2","key":"10362_CR11","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1093\/brain\/awq350","volume":"134","author":"L Lovato","year":"2011","unstructured":"Lovato L, Willis SN, Rodig SJ, Caron T, Almendinger SE, Howell OW, Reynolds R, O\u2019Connor KC, Hafler DA (2011) Related B cell clones populate the meninges and parenchyma of patients with multiple sclerosis. Brain 134(Pt 2):534\u2013541. https:\/\/doi.org\/10.1093\/brain\/awq350","journal-title":"Brain"},{"issue":"9","key":"10362_CR12","doi-asserted-by":"publisher","first-page":"5133","DOI":"10.4049\/jimmunol.163.9.5133","volume":"163","author":"SE Baranzini","year":"1999","unstructured":"Baranzini SE, Jeong MC, Butunoi C, Murray RS, Bernard CC, Oksenberg JR (1999) B cell repertoire diversity and clonal expansion in multiple sclerosis brain lesions. J Immunol 163(9):5133\u20135144","journal-title":"J Immunol"},{"issue":"5","key":"10362_CR13","doi-asserted-by":"publisher","first-page":"2725","DOI":"10.4049\/jimmunol.171.5.2725","volume":"171","author":"GP Owens","year":"2003","unstructured":"Owens GP, Ritchie AM, Burgoon MP, Williamson RA, Corboy JR, Gilden DH (2003) Single-cell repertoire analysis demonstrates that clonal expansion is a prominent feature of the B cell response in multiple sclerosis cerebrospinal fluid. J Immunol 171(5):2725\u20132733. https:\/\/doi.org\/10.4049\/jimmunol.171.5.2725","journal-title":"J Immunol"},{"issue":"5","key":"10362_CR14","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1172\/JCI3568","volume":"102","author":"Y Qin","year":"1998","unstructured":"Qin Y, Duquette P, Zhang Y, Talbot P, Poole R, Antel J (1998) Clonal expansion and somatic hypermutation of V(H) genes of B cells from cerebrospinal fluid in multiple sclerosis. J Clin Investig 102(5):1045\u20131050. https:\/\/doi.org\/10.1172\/JCI3568","journal-title":"J Clin Investig"},{"issue":"Pt 4","key":"10362_CR15","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1093\/brain\/awm038","volume":"130","author":"R Magliozzi","year":"2007","unstructured":"Magliozzi R, Howell O, Vora A, Serafini B, Nicholas R, Puopolo M, Reynolds R, Aloisi F (2007) Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 130(Pt 4):1089\u20131104. https:\/\/doi.org\/10.1093\/brain\/awm038","journal-title":"Brain"},{"issue":"1","key":"10362_CR16","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/ana.25119","volume":"83","author":"AL Greenfield","year":"2018","unstructured":"Greenfield AL, Hauser SL (2018) B-cell therapy for multiple sclerosis: entering an era. Ann Neurol 83(1):13\u201326. https:\/\/doi.org\/10.1002\/ana.25119","journal-title":"Ann Neurol"},{"issue":"11","key":"10362_CR17","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1212\/WNL.0b013e318249f6f0","volume":"78","author":"G Disanto","year":"2012","unstructured":"Disanto G, Morahan JM, Barnett MH, Giovannoni G, Ramagopalan SV (2012) The evidence for a role of B cells in multiple sclerosis. Neurology 78(11):823\u2013832. https:\/\/doi.org\/10.1212\/WNL.0b013e318249f6f0","journal-title":"Neurology"},{"issue":"1\u20132","key":"10362_CR18","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.jneuroim.2011.01.010","volume":"233","author":"B Obermeier","year":"2011","unstructured":"Obermeier B, Lovato L, Mentele R, Bruck W, Forne I, Imhof A, Lottspeich F, Turk KW, Willis SN, Wekerle H, Hohlfeld R, Hafler DA, O\u2019Connor KC, Dornmair K (2011) Related B cell clones that populate the CSF and CNS of patients with multiple sclerosis produce CSF immunoglobulin. J Neuroimmunol 233(1\u20132):245\u2013248. https:\/\/doi.org\/10.1016\/j.jneuroim.2011.01.010","journal-title":"J Neuroimmunol"},{"issue":"2","key":"10362_CR19","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1002\/ana.24088","volume":"75","author":"J Bankoti","year":"2014","unstructured":"Bankoti J, Apeltsin L, Hauser SL, Allen S, Albertolle ME, Witkowska HE, von Budingen HC (2014) In multiple sclerosis, oligoclonal bands connect to peripheral B-cell responses. Ann Neurol 75(2):266\u2013276. https:\/\/doi.org\/10.1002\/ana.24088","journal-title":"Ann Neurol"},{"issue":"Pt 6","key":"10362_CR20","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1093\/brain\/aws105","volume":"135","author":"C Elliott","year":"2012","unstructured":"Elliott C, Lindner M, Arthur A, Brennan K, Jarius S, Hussey J, Chan A, Stroet A, Olsson T, Willison H, Barnett SC, Meinl E, Linington C (2012) Functional identification of pathogenic autoantibody responses in patients with multiple sclerosis. Brain 135(Pt 6):1819\u20131833. https:\/\/doi.org\/10.1093\/brain\/aws105","journal-title":"Brain"},{"issue":"9485","key":"10362_CR21","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/S0140-6736(05)67102-4","volume":"366","author":"M Keegan","year":"2005","unstructured":"Keegan M, Konig F, McClelland R, Bruck W, Morales Y, Bitsch A, Panitch H, Lassmann H, Weinshenker B, Rodriguez M, Parisi J, Lucchinetti CF (2005) Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet 366(9485):579\u2013582. https:\/\/doi.org\/10.1016\/S0140-6736(05)67102-4","journal-title":"Lancet"},{"issue":"2","key":"10362_CR22","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1056\/NEJMoa022328","volume":"349","author":"T Berger","year":"2003","unstructured":"Berger T, Rubner P, Schautzer F, Egg R, Ulmer H, Mayringer I, Dilitz E, Deisenhammer F, Reindl M (2003) Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med 349(2):139\u2013145. https:\/\/doi.org\/10.1056\/NEJMoa022328","journal-title":"N Engl J Med"},{"issue":"4","key":"10362_CR23","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1111\/jnc.12005","volume":"123","author":"M Rouwette","year":"2012","unstructured":"Rouwette M, Somers K, Govarts C, De Deyn PP, Hupperts R, Van Wijmeersch B, De Jong BA, Verbeek MM, Van Pesch V, Sindic C, Villar LM, Alvarez-Cermeno JC, Stinissen P, Somers V (2012) Novel cerebrospinal fluid and serum autoantibody targets for clinically isolated syndrome. J Neurochem 123(4):568\u2013577. https:\/\/doi.org\/10.1111\/jnc.12005","journal-title":"J Neurochem"},{"issue":"2","key":"10362_CR24","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1111\/j.1750-3639.2004.tb00049.x","volume":"14","author":"B Serafini","year":"2004","unstructured":"Serafini B, Rosicarelli B, Magliozzi R, Stigliano E, Aloisi F (2004) Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol 14(2):164\u2013174. https:\/\/doi.org\/10.1111\/j.1750-3639.2004.tb00049.x","journal-title":"Brain Pathol"},{"issue":"6","key":"10362_CR25","doi-asserted-by":"publisher","first-page":"3498","DOI":"10.4049\/jimmunol.176.6.3498","volume":"176","author":"A Crawford","year":"2006","unstructured":"Crawford A, Macleod M, Schumacher T, Corlett L, Gray D (2006) Primary T cell expansion and differentiation in vivo requires antigen presentation by B cells. J Immunol 176(6):3498\u20133506. https:\/\/doi.org\/10.4049\/jimmunol.176.6.3498","journal-title":"J Immunol"},{"issue":"9","key":"10362_CR26","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1177\/1352458514560923","volume":"21","author":"LL Aung","year":"2015","unstructured":"Aung LL, Balashov KE (2015) Decreased Dicer expression is linked to increased expression of co-stimulatory molecule CD80 on B cells in multiple sclerosis. Mult Scler 21(9):1131\u20131138. https:\/\/doi.org\/10.1177\/1352458514560923","journal-title":"Mult Scler"},{"issue":"3","key":"10362_CR27","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s00281-014-0424-x","volume":"36","author":"M Krumbholz","year":"2014","unstructured":"Krumbholz M, Meinl E (2014) B cells in MS and NMO: pathogenesis and therapy. Semin Immunopathol 36(3):339\u2013350. https:\/\/doi.org\/10.1007\/s00281-014-0424-x","journal-title":"Semin Immunopathol"},{"issue":"11","key":"10362_CR28","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1001\/jamaneurol.2014.1472","volume":"71","author":"SJ Ireland","year":"2014","unstructured":"Ireland SJ, Guzman AA, O\u2019Brien DE, Hughes S, Greenberg B, Flores A, Graves D, Remington G, Frohman EM, Davis LS, Monson NL (2014) The effect of glatiramer acetate therapy on functional properties of B cells from patients with relapsing-remitting multiple sclerosis. JAMA Neurol 71(11):1421\u20131428. https:\/\/doi.org\/10.1001\/jamaneurol.2014.1472","journal-title":"JAMA Neurol"},{"issue":"12","key":"10362_CR29","doi-asserted-by":"publisher","first-page":"3701","DOI":"10.3390\/v4123701","volume":"4","author":"A Lossius","year":"2012","unstructured":"Lossius A, Johansen JN, Torkildsen O, Vartdal F, Holmoy T (2012) Epstein-Barr virus in systemic lupus erythematosus, rheumatoid arthritis and multiple sclerosis-association and causation. Viruses 4(12):3701\u20133730. https:\/\/doi.org\/10.3390\/v4123701","journal-title":"Viruses"},{"issue":"3","key":"10362_CR30","doi-asserted-by":"publisher","first-page":"e308","DOI":"10.1212\/NXI.0000000000000308","volume":"4","author":"J Endriz","year":"2017","unstructured":"Endriz J, Ho PP, Steinman L (2017) Time correlation between mononucleosis and initial symptoms of MS. Neurol Neuroimmunol Neuroinflamm 4(3):e308. https:\/\/doi.org\/10.1212\/NXI.0000000000000308","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"7","key":"10362_CR31","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1056\/NEJMoa0706383","volume":"358","author":"SL Hauser","year":"2008","unstructured":"Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, Bar-Or A, Panzara M, Sarkar N, Agarwal S, Langer-Gould A, Smith CH, HERMES Trial Group (2008) B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358(7):676\u2013688. https:\/\/doi.org\/10.1056\/NEJMoa0706383","journal-title":"N Engl J Med"},{"key":"10362_CR32","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ebiom.2017.01.042","volume":"16","author":"D Baker","year":"2017","unstructured":"Baker D, Marta M, Pryce G, Giovannoni G, Schmierer K (2017) Memory B cells are major targets for effective immunotherapy in relapsing multiple sclerosis. EBioMedicine 16:41\u201350. https:\/\/doi.org\/10.1016\/j.ebiom.2017.01.042","journal-title":"EBioMedicine"},{"key":"10362_CR33","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1159\/000082102","volume":"8","author":"MS Cragg","year":"2005","unstructured":"Cragg MS, Walshe CA, Ivanov AO, Glennie MJ (2005) The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun 8:140\u2013174. https:\/\/doi.org\/10.1159\/000082102","journal-title":"Curr Dir Autoimmun"},{"issue":"10","key":"10362_CR34","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.3390\/ijms18102048","volume":"18","author":"K Lehmann-Horn","year":"2017","unstructured":"Lehmann-Horn K, Kinzel S, Weber MS (2017) Deciphering the role of B cells in multiple sclerosis-towards specific targeting of pathogenic function. Int J Mol Sci 18(10):2048. https:\/\/doi.org\/10.3390\/ijms18102048","journal-title":"Int J Mol Sci"},{"key":"10362_CR35","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1146\/annurev-med-042910-135833","volume":"63","author":"D Ontaneda","year":"2012","unstructured":"Ontaneda D, Hyland M, Cohen JA (2012) Multiple sclerosis: new insights in pathogenesis and novel therapeutics. Annu Rev Med 63:389\u2013404. https:\/\/doi.org\/10.1146\/annurev-med-042910-135833","journal-title":"Annu Rev Med"},{"issue":"20","key":"10362_CR36","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1212\/WNL.0000000000003331","volume":"87","author":"J Salzer","year":"2016","unstructured":"Salzer J, Svenningsson R, Alping P, Novakova L, Bjorck A, Fink K, Islam-Jakobsson P, Malmestrom C, Axelsson M, Vagberg M, Sundstrom P, Lycke J, Piehl F, Svenningsson A (2016) Rituximab in multiple sclerosis: a retrospective observational study on safety and efficacy. Neurology 87(20):2074\u20132081. https:\/\/doi.org\/10.1212\/WNL.0000000000003331","journal-title":"Neurology"},{"issue":"4","key":"10362_CR37","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1002\/ana.21867","volume":"66","author":"K Hawker","year":"2009","unstructured":"Hawker K, O\u2019Connor P, Freedman MS, Calabresi PA, Antel J, Simon J, Hauser S, Waubant E, Vollmer T, Panitch H, Zhang J, Chin P, Smith CH, OLYMPUS trial group (2009) Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 66(4):460\u2013471. https:\/\/doi.org\/10.1002\/ana.21867","journal-title":"Ann Neurol"},{"key":"10362_CR38","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.msard.2018.09.041","volume":"27","author":"E D'Amico","year":"2019","unstructured":"D\u2019Amico E, Zanghi A, Chisari CG, Fermo SL, Toscano S, Arena S, Patti F, Zappia M (2019) Effectiveness and safety of Rituximab in demyelinating diseases spectrum: an Italian experience. Mult Scler Relat Disord 27:324\u2013326. https:\/\/doi.org\/10.1016\/j.msard.2018.09.041","journal-title":"Mult Scler Relat Disord"},{"issue":"11","key":"10362_CR39","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1007\/s40262-015-0296-9","volume":"54","author":"D Ternant","year":"2015","unstructured":"Ternant D, Bejan-Angoulvant T, Passot C, Mulleman D, Paintaud G (2015) Clinical pharmacokinetics and pharmacodynamics of monoclonal antibodies approved to treat rheumatoid arthritis. Clin Pharmacokinet 54(11):1107\u20131123. https:\/\/doi.org\/10.1007\/s40262-015-0296-9","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"10362_CR40","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1177\/0091270005277075","volume":"45","author":"CM Ng","year":"2005","unstructured":"Ng CM, Bruno R, Combs D, Davies B (2005) Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial. J Clin Pharmacol 45(7):792\u2013801. https:\/\/doi.org\/10.1177\/0091270005277075","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"10362_CR41","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1002\/ana.21363","volume":"63","author":"A Bar-Or","year":"2008","unstructured":"Bar-Or A, Calabresi PA, Arnold D, Markowitz C, Shafer S, Kasper LH, Waubant E, Gazda S, Fox RJ, Panzara M, Sarkar N, Agarwal S, Smith CH (2008) Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol 63(3):395\u2013400. https:\/\/doi.org\/10.1002\/ana.21363","journal-title":"Ann Neurol"},{"issue":"1","key":"10362_CR42","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/s41572-018-0041-4","volume":"4","author":"M Filippi","year":"2018","unstructured":"Filippi M, Bar-Or A, Piehl F, Preziosa P, Solari A, Vukusic S, Rocca MA (2018) Multiple sclerosis. Nat Rev Dis Primers 4(1):43. https:\/\/doi.org\/10.1038\/s41572-018-0041-4","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"10362_CR43","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1177\/1352458517704507","volume":"24","author":"MH Hagens","year":"2018","unstructured":"Hagens MH, Killestein J, Yaqub MM, van Dongen GA, Lammertsma AA, Barkhof F, van Berckel BN (2018) Cerebral rituximab uptake in multiple sclerosis: a (89)Zr-immunoPET pilot study. Mult Scler 24(4):543\u2013545. https:\/\/doi.org\/10.1177\/1352458517704507","journal-title":"Mult Scler"},{"issue":"2","key":"10362_CR44","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1177\/1352458508098268","volume":"15","author":"HF Petereit","year":"2009","unstructured":"Petereit HF, Rubbert-Roth A (2009) Rituximab levels in cerebrospinal fluid of patients with neurological autoimmune disorders. Mult Scler 15(2):189\u2013192. https:\/\/doi.org\/10.1177\/1352458508098268","journal-title":"Mult Scler"},{"issue":"3","key":"10362_CR45","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1002\/acn3.293","volume":"3","author":"M Komori","year":"2016","unstructured":"Komori M, Lin YC, Cortese I, Blake A, Ohayon J, Cherup J, Maric D, Kosa P, Wu T, Bielekova B (2016) Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis. Ann Clin Transl Neurol 3(3):166\u2013179. https:\/\/doi.org\/10.1002\/acn3.293","journal-title":"Ann Clin Transl Neurol"},{"issue":"11","key":"10362_CR46","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1200\/JCO.2006.09.7311","volume":"25","author":"JL Rubenstein","year":"2007","unstructured":"Rubenstein JL, Fridlyand J, Abrey L, Shen A, Karch J, Wang E, Issa S, Damon L, Prados M, McDermott M, O\u2019Brien J, Haqq C, Shuman M (2007) Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J Clin Oncol 25(11):1350\u20131356. https:\/\/doi.org\/10.1200\/JCO.2006.09.7311","journal-title":"J Clin Oncol"},{"issue":"1","key":"10362_CR47","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1046\/j.1471-4159.2002.00840.x","volume":"81","author":"F Schlachetzki","year":"2002","unstructured":"Schlachetzki F, Zhu C, Pardridge WM (2002) Expression of the neonatal Fc receptor (FcRn) at the blood-brain barrier. J Neurochem 81(1):203\u2013206. https:\/\/doi.org\/10.1046\/j.1471-4159.2002.00840.x","journal-title":"J Neurochem"},{"issue":"2","key":"10362_CR48","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1182\/blood-2002-06-1636","volume":"101","author":"JL Rubenstein","year":"2003","unstructured":"Rubenstein JL, Combs D, Rosenberg J, Levy A, McDermott M, Damon L, Ignoffo R, Aldape K, Shen A, Lee D, Grillo-Lopez A, Shuman MA (2003) Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood 101(2):466\u2013468. https:\/\/doi.org\/10.1182\/blood-2002-06-1636","journal-title":"Blood"},{"key":"10362_CR49","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.msard.2016.01.001","volume":"6","author":"J Topping","year":"2016","unstructured":"Topping J, Dobson R, Lapin S, Maslyanskiy A, Kropshofer H, Leppert D, Giovannoni G, Evdoshenko E (2016) The effects of intrathecal rituximab on biomarkers in multiple sclerosis. Mult Scler Relat Disord 6:49\u201353. https:\/\/doi.org\/10.1016\/j.msard.2016.01.001","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"10362_CR50","doi-asserted-by":"publisher","first-page":"22","DOI":"10.4161\/mabs.22771","volume":"5","author":"C Klein","year":"2013","unstructured":"Klein C, Lammens A, Schafer W, Georges G, Schwaiger M, Mossner E, Hopfner KP, Umana P, Niederfellner G (2013) Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties. MAbs 5(1):22\u201333. https:\/\/doi.org\/10.4161\/mabs.22771","journal-title":"MAbs"},{"issue":"9","key":"10362_CR51","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1093\/annonc\/mdq027","volume":"21","author":"F Morschhauser","year":"2010","unstructured":"Morschhauser F, Marlton P, Vitolo U, Linden O, Seymour JF, Crump M, Coiffier B, Foa R, Wassner E, Burger HU, Brennan B, Mendila M (2010) Results of a phase I\/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed\/refractory follicular lymphoma. Ann Oncol 21(9):1870\u20131876. https:\/\/doi.org\/10.1093\/annonc\/mdq027","journal-title":"Ann Oncol"},{"issue":"1","key":"10362_CR52","doi-asserted-by":"publisher","first-page":"749","DOI":"10.4049\/jimmunol.0900632","volume":"183","author":"AW Pawluczkowycz","year":"2009","unstructured":"Pawluczkowycz AW, Beurskens FJ, Beum PV, Lindorfer MA, van de Winkel JG, Parren PW, Taylor RP (2009) Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX. J Immunol 183(1):749\u2013758. https:\/\/doi.org\/10.4049\/jimmunol.0900632","journal-title":"J Immunol"},{"issue":"1","key":"10362_CR53","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2165\/11539590-000000000-00000","volume":"25","author":"T Robak","year":"2011","unstructured":"Robak T, Robak E (2011) New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies. BioDrugs 25(1):13\u201325. https:\/\/doi.org\/10.2165\/11539590-000000000-00000","journal-title":"BioDrugs"},{"key":"10362_CR54","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1182\/asheducation-2007.1.226","volume":"2007","author":"DG Maloney","year":"2007","unstructured":"Maloney DG (2007) Follicular NHL: from antibodies and vaccines to graft-versus-lymphoma effects. Hematology Am Soc Hematol Educ Program 2007:226\u2013232. https:\/\/doi.org\/10.1182\/asheducation-2007.1.226","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"10","key":"10362_CR55","doi-asserted-by":"publisher","first-page":"3266","DOI":"10.1200\/JCO.1997.15.10.3266","volume":"15","author":"DG Maloney","year":"1997","unstructured":"Maloney DG, Grillo-Lopez AJ, Bodkin DJ, White CA, Liles TM, Royston I, Varns C, Rosenberg J, Levy R (1997) IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin\u2019s lymphoma. J Clin Oncol 15(10):3266\u20133274. https:\/\/doi.org\/10.1200\/JCO.1997.15.10.3266","journal-title":"J Clin Oncol"},{"issue":"6","key":"10362_CR56","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1001\/archneurol.2010.99","volume":"67","author":"L Piccio","year":"2010","unstructured":"Piccio L, Naismith RT, Trinkaus K, Klein RS, Parks BJ, Lyons JA, Cross AH (2010) Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis. Arch Neurol 67(6):707\u2013714. https:\/\/doi.org\/10.1001\/archneurol.2010.99","journal-title":"Arch Neurol"},{"issue":"4","key":"10362_CR57","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1002\/ana.21939","volume":"67","author":"A Bar-Or","year":"2010","unstructured":"Bar-Or A, Fawaz L, Fan B, Darlington PJ, Rieger A, Ghorayeb C, Calabresi PA, Waubant E, Hauser SL, Zhang J, Smith CH (2010) Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS? Ann Neurol 67(4):452\u2013461. https:\/\/doi.org\/10.1002\/ana.21939","journal-title":"Ann Neurol"},{"issue":"310","key":"10362_CR58","doi-asserted-by":"publisher","first-page":"310ra166","DOI":"10.1126\/scitranslmed.aab4176","volume":"7","author":"R Li","year":"2015","unstructured":"Li R, Rezk A, Miyazaki Y, Hilgenberg E, Touil H, Shen P, Moore CS, Michel L, Althekair F, Rajasekharan S, Gommerman JL, Prat A, Fillatreau S, Bar-Or A, Canadian BciMST (2015) Proinflammatory GM-CSF-producing B cells in multiple sclerosis and B cell depletion therapy. Sci Transl Med 7(310):310ra166. https:\/\/doi.org\/10.1126\/scitranslmed.aab4176","journal-title":"Sci Transl Med"},{"issue":"2","key":"10362_CR59","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.msard.2013.10.003","volume":"3","author":"J Graves","year":"2014","unstructured":"Graves J, Vinayagasundaram U, Mowry EM, Matthews IR, Marino JA, Cheng J, Waubant E (2014) Effects of rituximab on lymphocytes in multiple sclerosis and neuromyelitis optica. Mult Scler Relat Disord 3(2):244\u2013252. https:\/\/doi.org\/10.1016\/j.msard.2013.10.003","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"10362_CR60","doi-asserted-by":"publisher","first-page":"580","DOI":"10.4049\/jimmunol.1400118","volume":"193","author":"A Palanichamy","year":"2014","unstructured":"Palanichamy A, Jahn S, Nickles D, Derstine M, Abounasr A, Hauser SL, Baranzini SE, Leppert D, von Budingen HC (2014) Rituximab efficiently depletes increased CD20-expressing T cells in multiple sclerosis patients. J Immunol 193(2):580\u2013586. https:\/\/doi.org\/10.4049\/jimmunol.1400118","journal-title":"J Immunol"},{"issue":"1","key":"10362_CR61","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/nrneurol.2016.187","volume":"13","author":"T Olsson","year":"2017","unstructured":"Olsson T, Barcellos LF, Alfredsson L (2017) Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis. Nat Rev Neurol 13(1):25\u201336. https:\/\/doi.org\/10.1038\/nrneurol.2016.187","journal-title":"Nat Rev Neurol"},{"issue":"3","key":"10362_CR62","doi-asserted-by":"publisher","first-page":"373","DOI":"10.4103\/1673-5374.245462","volume":"14","author":"Y Guan","year":"2019","unstructured":"Guan Y, Jakimovski D, Ramanathan M, Weinstock-Guttman B, Zivadinov R (2019) The role of Epstein-Barr virus in multiple sclerosis: from molecular pathophysiology to in vivo imaging. Neural Regen Res 14(3):373\u2013386. https:\/\/doi.org\/10.4103\/1673-5374.245462","journal-title":"Neural Regen Res"},{"issue":"23","key":"10362_CR63","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1212\/WNL.0b013e3181e24373","volume":"74","author":"RT Naismith","year":"2010","unstructured":"Naismith RT, Piccio L, Lyons JA, Lauber J, Tutlam NT, Parks BJ, Trinkaus K, Song SK, Cross AH (2010) Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial. Neurology 74(23):1860\u20131867. https:\/\/doi.org\/10.1212\/WNL.0b013e3181e24373","journal-title":"Neurology"},{"issue":"6","key":"10362_CR64","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1002\/ana.24651","volume":"79","author":"P Alping","year":"2016","unstructured":"Alping P, Frisell T, Novakova L, Islam-Jakobsson P, Salzer J, Bjorck A, Axelsson M, Malmestrom C, Fink K, Lycke J, Svenningsson A, Piehl F (2016) Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Ann Neurol 79(6):950\u2013958. https:\/\/doi.org\/10.1002\/ana.24651","journal-title":"Ann Neurol"},{"issue":"5","key":"10362_CR65","doi-asserted-by":"publisher","first-page":"e0197415","DOI":"10.1371\/journal.pone.0197415","volume":"13","author":"B Scotti","year":"2018","unstructured":"Scotti B, Disanto G, Sacco R, Guigli M, Zecca C, Gobbi C (2018) Effectiveness and safety of Rituximab in multiple sclerosis: an observational study from Southern Switzerland. PLoS ONE 13(5):e0197415. https:\/\/doi.org\/10.1371\/journal.pone.0197415","journal-title":"PLoS ONE"},{"issue":"3","key":"10362_CR66","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1001\/jamaneurol.2017.4011","volume":"75","author":"M Granqvist","year":"2018","unstructured":"Granqvist M, Boremalm M, Poorghobad A, Svenningsson A, Salzer J, Frisell T, Piehl F (2018) Comparative effectiveness of rituximab and other initial treatment choices for multiple sclerosis. JAMA Neurol 75(3):320\u2013327. https:\/\/doi.org\/10.1001\/jamaneurol.2017.4011","journal-title":"JAMA Neurol"},{"issue":"7","key":"10362_CR67","doi-asserted-by":"publisher","first-page":"e723","DOI":"10.1212\/WNL.0000000000006916","volume":"92","author":"JM Honce","year":"2019","unstructured":"Honce JM, Nair KV, Sillau S, Valdez B, Miravalle A, Alvarez E, Schreiner T, Corboy JR, Vollmer TL (2019) Rituximab vs placebo induction prior to glatiramer acetate monotherapy in multiple sclerosis. Neurology 92(7):e723\u2013e732. https:\/\/doi.org\/10.1212\/WNL.0000000000006916","journal-title":"Neurology"},{"issue":"2","key":"10362_CR68","doi-asserted-by":"publisher","first-page":"117","DOI":"10.2165\/11585960-000000000-00000","volume":"34","author":"BA Brown","year":"2011","unstructured":"Brown BA, Torabi M (2011) Incidence of infusion-associated reactions with rituximab for treating multiple sclerosis: a retrospective analysis of patients treated at a US centre. Drug Saf 34(2):117\u2013123. https:\/\/doi.org\/10.2165\/11585960-000000000-00000","journal-title":"Drug Saf"},{"issue":"9","key":"10362_CR69","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1177\/1352458517720044","volume":"24","author":"N Dunn","year":"2018","unstructured":"Dunn N, Juto A, Ryner M, Manouchehrinia A, Piccoli L, Fink K, Piehl F, Fogdell-Hahn A (2018) Rituximab in multiple sclerosis: frequency and clinical relevance of anti-drug antibodies. Mult Scler 24(9):1224\u20131233. https:\/\/doi.org\/10.1177\/1352458517720044","journal-title":"Mult Scler"},{"issue":"5","key":"10362_CR70","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.autrev.2019.03.011","volume":"18","author":"Y Hu","year":"2019","unstructured":"Hu Y, Nie H, Yu HH, Qin C, Wu LJ, Tang ZP, Tian DS (2019) Efficacy and safety of rituximab for relapsing-remitting multiple sclerosis: a systematic review and meta-analysis. Autoimmun Rev 18(5):542\u2013548. https:\/\/doi.org\/10.1016\/j.autrev.2019.03.011","journal-title":"Autoimmun Rev"},{"issue":"4","key":"10362_CR71","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.autrev.2018.12.002","volume":"18","author":"C Salvarani","year":"2019","unstructured":"Salvarani C, Brown RD Jr, Muratore F, Christianson TJH, Galli E, Pipitone N, Cassone G, Huston J III, Giannini C, Warrington K, Hunder GG (2019) Rituximab therapy for primary central nervous system vasculitis: a 6 patient experience and review of the literature. Autoimmun Rev 18(4):399\u2013405. https:\/\/doi.org\/10.1016\/j.autrev.2018.12.002","journal-title":"Autoimmun Rev"},{"key":"10362_CR72","unstructured":"Alvarez KNIS E, Sillau S, Vollmer T (2019) Tolerability and safety of switching from rituximab to ocrelizumab: evaluating factors associated with infusion related reactions\u2014Abstract: P1402. ECTRIMS Online Library. Alvarez E. 09\/13\/19; 278602"},{"issue":"Suppl 10","key":"10362_CR73","doi-asserted-by":"publisher","first-page":"x313","DOI":"10.1093\/annonc\/mds314","volume":"23","author":"M Joerger","year":"2012","unstructured":"Joerger M (2012) Prevention and handling of acute allergic and infusion reactions in oncology. Ann Oncol 23(Suppl 10):x313-319. https:\/\/doi.org\/10.1093\/annonc\/mds314","journal-title":"Ann Oncol"},{"issue":"6","key":"10362_CR74","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s10067-014-2509-2","volume":"33","author":"M Heusele","year":"2014","unstructured":"Heusele M, Clerson P, Guery B, Lambert M, Launay D, Lefevre G, Morell-Dubois S, Maillard H, Le Gouellec N, Hatron PY, Hachulla E (2014) Risk factors for severe bacterial infections in patients with systemic autoimmune diseases receiving rituximab. Clin Rheumatol 33(6):799\u2013805. https:\/\/doi.org\/10.1007\/s10067-014-2509-2","journal-title":"Clin Rheumatol"},{"issue":"9","key":"10362_CR75","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1002\/art.27555","volume":"62","author":"JE Gottenberg","year":"2010","unstructured":"Gottenberg JE, Ravaud P, Bardin T, Cacoub P, Cantagrel A, Combe B, Dougados M, Flipo RM, Godeau B, Guillevin L, Le Loet X, Hachulla E, Schaeverbeke T, Sibilia J, Baron G, Mariette X, AutoImmunity and Rituximab registry and French Society of Rheumatology (2010) Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis Rheum 62(9):2625\u20132632. https:\/\/doi.org\/10.1002\/art.27555","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10362_CR76","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1053\/j.seminhematol.2010.01.002","volume":"47","author":"JC Gea-Banacloche","year":"2010","unstructured":"Gea-Banacloche JC (2010) Rituximab-associated infections. Semin Hematol 47(2):187\u2013198. https:\/\/doi.org\/10.1053\/j.seminhematol.2010.01.002","journal-title":"Semin Hematol"},{"key":"10362_CR77","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2019.3365","author":"G Luna","year":"2019","unstructured":"Luna G, Alping P, Burman J, Fink K, Fogdell-Hahn A, Gunnarsson M, Hillert J, Langer-Gould A, Lycke J, Nilsson P, Salzer J, Svenningsson A, Vrethem M, Olsson T, Piehl F, Frisell T (2019) Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurol. https:\/\/doi.org\/10.1001\/jamaneurol.2019.3365","journal-title":"JAMA Neurol"},{"issue":"12","key":"10362_CR78","doi-asserted-by":"publisher","first-page":"3896","DOI":"10.1002\/art.23059","volume":"56","author":"E Keystone","year":"2007","unstructured":"Keystone E, Fleischmann R, Emery P, Furst DE, van Vollenhoven R, Bathon J, Dougados M, Baldassare A, Ferraccioli G, Chubick A, Udell J, Cravets MW, Agarwal S, Cooper S, Magrini F (2007) Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum 56(12):3896\u20133908. https:\/\/doi.org\/10.1002\/art.23059","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10362_CR79","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1007\/s00415-015-7979-x","volume":"263","author":"J Salzer","year":"2016","unstructured":"Salzer J, Lycke J, Wickstrom R, Naver H, Piehl F, Svenningsson A (2016) Rituximab in paediatric onset multiple sclerosis: a case series. J Neurol 263(2):322\u2013326. https:\/\/doi.org\/10.1007\/s00415-015-7979-x","journal-title":"J Neurol"},{"issue":"6","key":"10362_CR80","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1177\/1352458518772748","volume":"25","author":"P Durozard","year":"2019","unstructured":"Durozard P, Maarouf A, Boutiere C, Ruet A, Brochet B, Vukusic S, Carra-Dalliere C, Labauge P, Mathey G, Debouverie M, Papeix C, Maillart E, Lubetzki C, Bensa C, Gout O, Giannesini C, Stankoff B, Ciron J, Brassat D, Pelletier J, Rico Lamy A, Audoin B (2019) Efficacy of rituximab in refractory RRMS. Mult Scler 25(6):828\u2013836. https:\/\/doi.org\/10.1177\/1352458518772748","journal-title":"Mult Scler"},{"issue":"2","key":"10362_CR81","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1212\/WNL.0000000000002832","volume":"87","author":"P de Flon","year":"2016","unstructured":"de Flon P, Gunnarsson M, Laurell K, Soderstrom L, Birgander R, Lindqvist T, Krauss W, Dring A, Bergman J, Sundstrom P, Svenningsson A (2016) Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to rituximab. Neurology 87(2):141\u2013147. https:\/\/doi.org\/10.1212\/WNL.0000000000002832","journal-title":"Neurology"},{"issue":"1","key":"10362_CR82","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11481-015-9646-5","volume":"11","author":"PS Rommer","year":"2016","unstructured":"Rommer PS, Dorner T, Freivogel K, Haas J, Kieseier BC, Kumpfel T, Paul F, Proft F, Schulze-Koops H, Schmidt E, Wiendl H, Ziemann U, Zettl UK, GRAID Investigators (2016) Safety and clinical outcomes of rituximab treatment in patients with multiple sclerosis and neuromyelitis optica: experience from a National Online Registry (GRAID). J Neuroimmune Pharmacol 11(1):1\u20138. https:\/\/doi.org\/10.1007\/s11481-015-9646-5","journal-title":"J Neuroimmune Pharmacol"},{"issue":"2","key":"10362_CR83","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1097\/WNF.0000000000000268","volume":"41","author":"B Alldredge","year":"2018","unstructured":"Alldredge B, Jordan A, Imitola J, Racke MK (2018) Safety and efficacy of rituximab: experience of a single multiple sclerosis center. Clin Neuropharmacol 41(2):56\u201359. https:\/\/doi.org\/10.1097\/WNF.0000000000000268","journal-title":"Clin Neuropharmacol"},{"issue":"3","key":"10362_CR84","doi-asserted-by":"publisher","first-page":"R75","DOI":"10.1186\/ar3337","volume":"13","author":"HP Tony","year":"2011","unstructured":"Tony HP, Burmester G, Schulze-Koops H, Grunke M, Henes J, Kotter I, Haas J, Unger L, Lovric S, Haubitz M, Fischer-Betz R, Chehab G, Rubbert-Roth A, Specker C, Weinerth J, Holle J, Muller-Ladner U, Konig R, Fiehn C, Burgwinkel P, Budde K, Sorensen H, Meurer M, Aringer M, Kieseier B, Erfurt-Berge C, Sticherling M, Veelken R, Ziemann U, Strutz F, von Wussow P, Meier FM, Hunzelmann N, Schmidt E, Bergner R, Schwarting A, Eming R, Hertl M, Stadler R, Schwarz-Eywill M, Wassenberg S, Fleck M, Metzler C, Zettl U, Westphal J, Heitmann S, Herzog AL, Wiendl H, Jakob W, Schmidt E, Freivogel K, Dorner T, GRAID Investigators (2011) Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). Arthritis Res Ther 13(3):R75. https:\/\/doi.org\/10.1186\/ar3337","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"10362_CR85","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1111\/ane.13225","volume":"141","author":"J Hellgren","year":"2020","unstructured":"Hellgren J, Risedal A, Kallen K (2020) Rituximab in multiple sclerosis at general hospital level. Acta Neurol Scand 141(6):491\u2013499. https:\/\/doi.org\/10.1111\/ane.13225","journal-title":"Acta Neurol Scand"},{"key":"10362_CR86","doi-asserted-by":"publisher","first-page":"87","DOI":"10.2147\/DDDT.S41645","volume":"8","author":"CC Mok","year":"2013","unstructured":"Mok CC (2013) Rituximab for the treatment of rheumatoid arthritis: an update. Drug Des Devel Ther 8:87\u2013100. https:\/\/doi.org\/10.2147\/DDDT.S41645","journal-title":"Drug Des Devel Ther"},{"issue":"3","key":"10362_CR87","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s00296-009-1202-2","volume":"31","author":"A Pyrpasopoulou","year":"2011","unstructured":"Pyrpasopoulou A, Douma S, Vassiliadis T, Chatzimichailidou S, Triantafyllou A, Aslanidis S (2011) Reactivation of chronic hepatitis B virus infection following rituximab administration for rheumatoid arthritis. Rheumatol Int 31(3):403\u2013404. https:\/\/doi.org\/10.1007\/s00296-009-1202-2","journal-title":"Rheumatol Int"},{"issue":"5","key":"10362_CR88","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1186\/s40880-015-0015-9","volume":"34","author":"KL Chen","year":"2015","unstructured":"Chen KL, Chen J, Rao HL, Guo Y, Huang HQ, Zhang L, Shao JY, Lin TY, Jiang WQ, Zou DH, Hu LY, Wirian ML, Cai QQ (2015) Hepatitis B virus reactivation and hepatitis in diffuse large B-cell lymphoma patients with resolved hepatitis B receiving rituximab-containing chemotherapy: risk factors and survival. Chin J Cancer 34(5):225\u2013234. https:\/\/doi.org\/10.1186\/s40880-015-0015-9","journal-title":"Chin J Cancer"},{"issue":"33","key":"10362_CR89","doi-asserted-by":"publisher","first-page":"3736","DOI":"10.1200\/JCO.2014.56.7081","volume":"32","author":"WK Seto","year":"2014","unstructured":"Seto WK, Chan TS, Hwang YY, Wong DK, Fung J, Liu KS, Gill H, Lam YF, Lie AK, Lai CL, Kwong YL, Yuen MF (2014) Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study. J Clin Oncol 32(33):3736\u20133743. https:\/\/doi.org\/10.1200\/JCO.2014.56.7081","journal-title":"J Clin Oncol"},{"issue":"2","key":"10362_CR90","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1002\/hep.27609","volume":"61","author":"AM Di Bisceglie","year":"2015","unstructured":"Di Bisceglie AM, Lok AS, Martin P, Terrault N, Perrillo RP, Hoofnagle JH (2015) Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg? Hepatology 61(2):703\u2013711. https:\/\/doi.org\/10.1002\/hep.27609","journal-title":"Hepatology"},{"key":"10362_CR91","unstructured":"(FDA) FaDA (2020) FDA Drug safety communication: boxed warning and new recommendations to decrease risk of hepatitis B reactivation with the immune-suppressing and anti-cancer drugs Arzerra (ofatumumab) and Rituxan (rituximab). https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-boxed-warning-and-new-recommendations-decrease-risk-hepatitis-b. Accessed Nov 2020"},{"issue":"4","key":"10362_CR92","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1182\/blood.v99.4.1486","volume":"99","author":"SL Goldberg","year":"2002","unstructured":"Goldberg SL, Pecora AL, Alter RS, Kroll MS, Rowley SD, Waintraub SE, Imrit K, Preti RA (2002) Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab. Blood 99(4):1486\u20131488. https:\/\/doi.org\/10.1182\/blood.v99.4.1486","journal-title":"Blood"},{"issue":"4","key":"10362_CR93","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s12185-008-0066-7","volume":"87","author":"D Ennishi","year":"2008","unstructured":"Ennishi D, Terui Y, Yokoyama M, Mishima Y, Takahashi S, Takeuchi K, Ikeda K, Tanimoto M, Hatake K (2008) Increased incidence of interstitial pneumonia by CHOP combined with rituximab. Int J Hematol 87(4):393\u2013397. https:\/\/doi.org\/10.1007\/s12185-008-0066-7","journal-title":"Int J Hematol"},{"key":"10362_CR94","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2012-008142","author":"T Sikkema","year":"2013","unstructured":"Sikkema T, Schuiling WJ, Hoogendoorn M (2013) Progressive multifocal leukoencephalopathy during treatment with rituximab and CHOP chemotherapy in a patient with a diffuse large B-cell lymphoma. BMJ Case Rep. https:\/\/doi.org\/10.1136\/bcr-2012-008142","journal-title":"BMJ Case Rep"},{"issue":"8","key":"10362_CR95","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1177\/1352458518786075","volume":"25","author":"Y Oshima","year":"2019","unstructured":"Oshima Y, Tanimoto T, Yuji K, Tojo A (2019) Drug-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients. Mult Scler 25(8):1141\u20131149. https:\/\/doi.org\/10.1177\/1352458518786075","journal-title":"Mult Scler"},{"issue":"5","key":"10362_CR96","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/S1081-1206(10)60764-8","volume":"98","author":"S Narula","year":"2007","unstructured":"Narula S, LaRosa DF, Kamoun M, Dalmau J, Levinson AI (2007) Progressive multifocal leukoencephalopathy in a patient with common variable immunodeficiency and abnormal CD8+ T-cell subset distribution. Ann Allergy Asthma Immunol 98(5):483\u2013489. https:\/\/doi.org\/10.1016\/S1081-1206(10)60764-8","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"8","key":"10362_CR97","doi-asserted-by":"publisher","first-page":"2924","DOI":"10.1182\/blood-2007-02-068999","volume":"110","author":"R Stasi","year":"2007","unstructured":"Stasi R, Del Poeta G, Stipa E, Evangelista ML, Trawinska MM, Cooper N, Amadori S (2007) Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. Blood 110(8):2924\u20132930. https:\/\/doi.org\/10.1182\/blood-2007-02-068999","journal-title":"Blood"},{"issue":"6","key":"10362_CR98","doi-asserted-by":"publisher","first-page":"e498","DOI":"10.1212\/WNL.0000000000004926","volume":"90","author":"E Iacobaeus","year":"2018","unstructured":"Iacobaeus E, Burkill S, Bahmanyar S, Hakim R, Bystrom C, Fored M, Olsson T, Brundin L, Montgomery S (2018) The national incidence of PML in Sweden, 1988\u20132013. Neurology 90(6):e498\u2013e506. https:\/\/doi.org\/10.1212\/WNL.0000000000004926","journal-title":"Neurology"},{"key":"10362_CR99","unstructured":"Classifying PML risk with disease modifying therapies\u2014FormSus. (2020). http:\/\/formsus.datasus.gov.br\/novoimgarq\/58543\/13614899_312364.pdf"},{"issue":"5","key":"10362_CR100","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1007\/s13365-017-0561-9","volume":"23","author":"L Prosperini","year":"2017","unstructured":"Prosperini L, Scarpazza C, Imberti L, Cordioli C, De Rossi N, Capra R (2017) Age as a risk factor for early onset of natalizumab-related progressive multifocal leukoencephalopathy. J Neurovirol 23(5):742\u2013749. https:\/\/doi.org\/10.1007\/s13365-017-0561-9","journal-title":"J Neurovirol"},{"key":"10362_CR101","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2147\/DNND.S203405","volume":"9","author":"M Kartau","year":"2019","unstructured":"Kartau M, Sipila JO, Auvinen E, Palomaki M, Verkkoniemi-Ahola A (2019) Progressive Multifocal Leukoencephalopathy: current Insights. Degener Neurol Neuromuscul Dis 9:109\u2013121. https:\/\/doi.org\/10.2147\/DNND.S203405","journal-title":"Degener Neurol Neuromuscul Dis"},{"issue":"3","key":"10362_CR102","doi-asserted-by":"publisher","first-page":"102466","DOI":"10.1016\/j.autrev.2020.102466","volume":"19","author":"K Kridin","year":"2020","unstructured":"Kridin K, Ahmed AR (2020) Post-rituximab immunoglobulin M (IgM) hypogammaglobulinemia. Autoimmun Rev 19(3):102466. https:\/\/doi.org\/10.1016\/j.autrev.2020.102466","journal-title":"Autoimmun Rev"},{"issue":"11","key":"10362_CR103","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1084\/jem.189.11.1747","volume":"189","author":"P Schneider","year":"1999","unstructured":"Schneider P, MacKay F, Steiner V, Hofmann K, Bodmer JL, Holler N, Ambrose C, Lawton P, Bixler S, Acha-Orbea H, Valmori D, Romero P, Werner-Favre C, Zubler RH, Browning JL, Tschopp J (1999) BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 189(11):1747\u20131756. https:\/\/doi.org\/10.1084\/jem.189.11.1747","journal-title":"J Exp Med"},{"key":"10362_CR104","doi-asserted-by":"publisher","first-page":"423971","DOI":"10.1155\/2011\/423971","volume":"2011","author":"S Ireland","year":"2011","unstructured":"Ireland S, Monson N (2011) Potential impact of B cells on T cell function in multiple sclerosis. Mult Scler Int 2011:423971. https:\/\/doi.org\/10.1155\/2011\/423971","journal-title":"Mult Scler Int"},{"issue":"6","key":"10362_CR105","doi-asserted-by":"publisher","first-page":"e498","DOI":"10.1212\/NXI.0000000000000498","volume":"5","author":"A Marcinno","year":"2018","unstructured":"Marcinno A, Marnetto F, Valentino P, Martire S, Balbo A, Drago A, Leto M, Capobianco M, Panzica G, Bertolotto A (2018) Rituximab-induced hypogammaglobulinemia in patients with neuromyelitis optica spectrum disorders. Neurol Neuroimmunol Neuroinflamm 5(6):e498. https:\/\/doi.org\/10.1212\/NXI.0000000000000498","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10362_CR106","doi-asserted-by":"publisher","first-page":"18","DOI":"10.4103\/1735-1995.200275","volume":"22","author":"M Etemadifar","year":"2017","unstructured":"Etemadifar M, Salari M, Mirmosayyeb O, Serati M, Nikkhah R, Askari M, Fayyazi E (2017) Efficacy and safety of rituximab in neuromyelitis optica: review of evidence. J Res Med Sci 22:18. https:\/\/doi.org\/10.4103\/1735-1995.200275","journal-title":"J Res Med Sci"},{"issue":"2","key":"10362_CR107","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.semarthrit.2018.02.010","volume":"48","author":"G Boleto","year":"2018","unstructured":"Boleto G, Avouac J, Wipff J, Forien M, Dougados M, Roux C, Kahan A, Dieude P, Allanore Y (2018) Predictors of hypogammaglobulinemia during rituximab maintenance therapy in rheumatoid arthritis: a 12-year longitudinal multi-center study. Semin Arthritis Rheum 48(2):149\u2013154. https:\/\/doi.org\/10.1016\/j.semarthrit.2018.02.010","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"10362_CR108","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.jbspin.2011.12.004","volume":"79","author":"A Isvy","year":"2012","unstructured":"Isvy A, Meunier M, Gobeaux-Chenevier C, Maury E, Wipff J, Job-Deslandre C, Kahan A, Allanore Y (2012) Safety of rituximab in rheumatoid arthritis: a long-term prospective single-center study of gammaglobulin concentrations and infections. Joint Bone Spine 79(4):365\u2013369. https:\/\/doi.org\/10.1016\/j.jbspin.2011.12.004","journal-title":"Joint Bone Spine"},{"issue":"7","key":"10362_CR109","doi-asserted-by":"publisher","first-page":"e184169","DOI":"10.1001\/jamanetworkopen.2018.4169","volume":"1","author":"S Barmettler","year":"2018","unstructured":"Barmettler S, Ong MS, Farmer JR, Choi H, Walter J (2018) Association of immunoglobulin levels, infectious risk, and mortality with rituximab and hypogammaglobulinemia. JAMA Netw Open 1(7):e184169. https:\/\/doi.org\/10.1001\/jamanetworkopen.2018.4169","journal-title":"JAMA Netw Open"},{"issue":"10","key":"10362_CR110","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.3109\/10428194.2012.679266","volume":"53","author":"S Rozman","year":"2012","unstructured":"Rozman S, Sonc M, Novakovic BJ (2012) Late-onset neutropenia following primary treatment of diffuse large B-cell lymphoma with rituximab-containing therapy. Leuk Lymphoma 53(10):1945\u20131948. https:\/\/doi.org\/10.3109\/10428194.2012.679266","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10362_CR111","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1586\/EHM.11.62","volume":"4","author":"D Tesfa","year":"2011","unstructured":"Tesfa D, Palmblad J (2011) Late-onset neutropenia following rituximab therapy: incidence, clinical features and possible mechanisms. Expert Rev Hematol 4(6):619\u2013625. https:\/\/doi.org\/10.1586\/EHM.11.62","journal-title":"Expert Rev Hematol"},{"key":"10362_CR112","doi-asserted-by":"publisher","first-page":"102019","DOI":"10.1016\/j.msard.2020.102019","volume":"41","author":"J Rigal","year":"2020","unstructured":"Rigal J, Ciron J, Lepine Z, Biotti D (2020) Late-onset neutropenia after RITUXIMAB therapy for multiple sclerosis, neuromyelitis optica spectrum disorders and MOG-antibody-associated diseases. Mult Scler Relat Disord 41:102019. https:\/\/doi.org\/10.1016\/j.msard.2020.102019","journal-title":"Mult Scler Relat Disord"},{"issue":"7","key":"10362_CR113","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1007\/s00415-018-8899-3","volume":"265","author":"C Alcala","year":"2018","unstructured":"Alcala C, Gascon F, Perez-Miralles F, Gil-Perotin S, Navarre A, Bosca I, Coret F, Casanova B (2018) Efficacy and safety of rituximab in relapsing and progressive multiple sclerosis: a hospital-based study. J Neurol 265(7):1690\u20131697. https:\/\/doi.org\/10.1007\/s00415-018-8899-3","journal-title":"J Neurol"},{"key":"10362_CR114","doi-asserted-by":"publisher","first-page":"9084759","DOI":"10.1155\/2018\/9084759","volume":"2018","author":"BI Yamout","year":"2018","unstructured":"Yamout BI, El-Ayoubi NK, Nicolas J, El Kouzi Y, Khoury SJ, Zeineddine MM (2018) Safety and efficacy of rituximab in multiple sclerosis: a retrospective observational study. J Immunol Res 2018:9084759. https:\/\/doi.org\/10.1155\/2018\/9084759","journal-title":"J Immunol Res"},{"issue":"11","key":"10362_CR115","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1001\/jamainternmed.2017.4332","volume":"177","author":"H Wadstrom","year":"2017","unstructured":"Wadstrom H, Frisell T, Askling J, Anti-Rheumatic Therapy in Sweden (ARTIS) Study Group (2017) Malignant neoplasms in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors, tocilizumab, abatacept, or rituximab in clinical practice: a nationwide cohort study from Sweden. JAMA Intern Med 177(11):1605\u20131612. https:\/\/doi.org\/10.1001\/jamainternmed.2017.4332","journal-title":"JAMA Intern Med"},{"issue":"5","key":"10362_CR116","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1002\/ana.25701","volume":"87","author":"P Alping","year":"2020","unstructured":"Alping P, Askling J, Burman J, Fink K, Fogdell-Hahn A, Gunnarsson M, Hillert J, Langer-Gould A, Lycke J, Nilsson P, Salzer J, Svenningsson A, Vrethem M, Olsson T, Piehl F, Frisell T (2020) Cancer risk for fingolimod, natalizumab, and rituximab in multiple sclerosis patients. Ann Neurol 87(5):688\u2013699. https:\/\/doi.org\/10.1002\/ana.25701","journal-title":"Ann Neurol"},{"issue":"3","key":"10362_CR117","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa0909905","volume":"363","author":"JH Stone","year":"2010","unstructured":"Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Turkiewicz A, Tchao NK, Webber L, Ding L, Sejismundo LP, Mieras K, Weitzenkamp D, Ikle D, Seyfert-Margolis V, Mueller M, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh KA, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Specks U, RAVE-ITN Research Group (2010) Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 363(3):221\u2013232. https:\/\/doi.org\/10.1056\/NEJMoa0909905","journal-title":"N Engl J Med"},{"issue":"2","key":"10362_CR118","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1002\/art.37754","volume":"65","author":"CV Oddis","year":"2013","unstructured":"Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC, Barohn RJ, Feldman BM, Harris-Love MO, Koontz DC, Fertig N, Kelley SS, Pryber SL, Miller FW, Rockette HE, RIM Study Group (2013) Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 65(2):314\u2013324. https:\/\/doi.org\/10.1002\/art.37754","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10362_CR119","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1056\/NEJMoa1814427","volume":"381","author":"FC Fervenza","year":"2019","unstructured":"Fervenza FC, Appel GB, Barbour SJ, Rovin BH, Lafayette RA, Aslam N, Jefferson JA, Gipson PE, Rizk DV, Sedor JR, Simon JF, McCarthy ET, Brenchley P, Sethi S, Avila-Casado C, Beanlands H, Lieske JC, Philibert D, Li T, Thomas LF, Green DF, Juncos LA, Beara-Lasic L, Blumenthal SS, Sussman AN, Erickson SB, Hladunewich M, Canetta PA, Hebert LA, Leung N, Radhakrishnan J, Reich HN, Parikh SV, Gipson DS, Lee DK, da Costa BR, Juni P, Cattran DC, Investigators M (2019) Rituximab or cyclosporine in the treatment of membranous nephropathy. N Engl J Med 381(1):36\u201346. https:\/\/doi.org\/10.1056\/NEJMoa1814427","journal-title":"N Engl J Med"},{"issue":"3","key":"10362_CR120","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa0909169","volume":"363","author":"RB Jones","year":"2010","unstructured":"Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, Savage CO, Segelmark M, Tesar V, van Paassen P, Walsh D, Walsh M, Westman K, Jayne DR, European Vasculitis Study Group (2010) Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 363(3):211\u2013220. https:\/\/doi.org\/10.1056\/NEJMoa0909169","journal-title":"N Engl J Med"},{"issue":"2","key":"10362_CR121","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1210\/jc.2014-2572","volume":"100","author":"MN Stan","year":"2015","unstructured":"Stan MN, Garrity JA, Carranza Leon BG, Prabin T, Bradley EA, Bahn RS (2015) Randomized controlled trial of rituximab in patients with Graves\u2019 orbitopathy. J Clin Endocrinol Metab 100(2):432\u2013441. https:\/\/doi.org\/10.1210\/jc.2014-2572","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10362_CR122","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1212\/WNL.0b013e3182407982","volume":"78","author":"J Diaz-Manera","year":"2012","unstructured":"Diaz-Manera J, Martinez-Hernandez E, Querol L, Klooster R, Rojas-Garcia R, Suarez-Calvet X, Munoz-Blanco JL, Mazia C, Straasheijm KR, Gallardo E, Juarez C, Verschuuren JJ, Illa I (2012) Long-lasting treatment effect of rituximab in MuSK myasthenia. Neurology 78(3):189\u2013193. https:\/\/doi.org\/10.1212\/WNL.0b013e3182407982","journal-title":"Neurology"},{"issue":"11","key":"10362_CR123","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1136\/ard.2007.087023","volume":"67","author":"K Owczarczyk","year":"2008","unstructured":"Owczarczyk K, Hellmann M, Fliedner G, Rohrs T, Maizus K, Passon D, Hallek M, Rubbert A (2008) Clinical outcome and B cell depletion in patients with rheumatoid arthritis receiving rituximab monotherapy in comparison with patients receiving concomitant methotrexate. Ann Rheum Dis 67(11):1648\u20131649. https:\/\/doi.org\/10.1136\/ard.2007.087023","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10362_CR124","doi-asserted-by":"publisher","first-page":"917","DOI":"10.3899\/jrheum.090442","volume":"37","author":"PJ Mease","year":"2010","unstructured":"Mease PJ, Cohen S, Gaylis NB, Chubick A, Kaell AT, Greenwald M, Agarwal S, Yin M, Kelman A (2010) Efficacy and safety of retreatment in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors: results from the SUNRISE trial. J Rheumatol 37(5):917\u2013927. https:\/\/doi.org\/10.3899\/jrheum.090442","journal-title":"J Rheumatol"},{"key":"10362_CR125","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.3389\/fimmu.2019.01990","volume":"10","author":"C Kaegi","year":"2019","unstructured":"Kaegi C, Wuest B, Schreiner J, Steiner UC, Vultaggio A, Matucci A, Crowley C, Boyman O (2019) Systematic review of safety and efficacy of rituximab in treating immune-mediated disorders. Front Immunol 10:1990. https:\/\/doi.org\/10.3389\/fimmu.2019.01990","journal-title":"Front Immunol"},{"issue":"6","key":"10362_CR126","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.ctrv.2005.05.007","volume":"31","author":"E Kimby","year":"2005","unstructured":"Kimby E (2005) Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 31(6):456\u2013473. https:\/\/doi.org\/10.1016\/j.ctrv.2005.05.007","journal-title":"Cancer Treat Rev"},{"issue":"26","key":"10362_CR127","doi-asserted-by":"publisher","first-page":"6769","DOI":"10.1182\/blood-2011-08-372649","volume":"118","author":"OE Yri","year":"2011","unstructured":"Yri OE, Torfoss D, Hungnes O, Tierens A, Waalen K, Nordoy T, Dudman S, Kilander A, Wader KF, Ostenstad B, Ekanger R, Meyer P, Kolstad A (2011) Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment. Blood 118(26):6769\u20136771. https:\/\/doi.org\/10.1182\/blood-2011-08-372649","journal-title":"Blood"},{"issue":"11","key":"10362_CR128","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1182\/blood-2013-04-494096","volume":"122","author":"I Nazi","year":"2013","unstructured":"Nazi I, Kelton JG, Larche M, Snider DP, Heddle NM, Crowther MA, Cook RJ, Tinmouth AT, Mangel J, Arnold DM (2013) The effect of rituximab on vaccine responses in patients with immune thrombocytopenia. Blood 122(11):1946\u20131953. https:\/\/doi.org\/10.1182\/blood-2013-04-494096","journal-title":"Blood"},{"issue":"12","key":"10362_CR129","doi-asserted-by":"publisher","first-page":"e93222","DOI":"10.1172\/jci.insight.93222","volume":"2","author":"A Cho","year":"2017","unstructured":"Cho A, Bradley B, Kauffman R, Priyamvada L, Kovalenkov Y, Feldman R, Wrammert J (2017) Robust memory responses against influenza vaccination in pemphigus patients previously treated with rituximab. JCI Insight 2(12):e93222. https:\/\/doi.org\/10.1172\/jci.insight.93222","journal-title":"JCI Insight"},{"key":"10362_CR130","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1196\/annals.1313.014","volume":"1050","author":"BF Hoyer","year":"2005","unstructured":"Hoyer BF, Manz RA, Radbruch A, Hiepe F (2005) Long-lived plasma cells and their contribution to autoimmunity. Ann N Y Acad Sci 1050:124\u2013133. https:\/\/doi.org\/10.1196\/annals.1313.014","journal-title":"Ann N Y Acad Sci"},{"issue":"3","key":"10362_CR131","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.clim.2007.11.012","volume":"126","author":"JA Sutter","year":"2008","unstructured":"Sutter JA, Kwan-Morley J, Dunham J, Du YZ, Kamoun M, Albert D, Eisenberg RA, Luning Prak ET (2008) A longitudinal analysis of SLE patients treated with rituximab (anti-CD20): factors associated with B lymphocyte recovery. Clin Immunol 126(3):282\u2013290. https:\/\/doi.org\/10.1016\/j.clim.2007.11.012","journal-title":"Clin Immunol"},{"key":"10362_CR132","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.3389\/fimmu.2019.01883","volume":"10","author":"T Zrzavy","year":"2019","unstructured":"Zrzavy T, Kollaritsch H, Rommer PS, Boxberger N, Loebermann M, Wimmer I, Winkelmann A, Zettl UK (2019) Vaccination in multiple sclerosis: friend or foe? Front Immunol 10:1883. https:\/\/doi.org\/10.3389\/fimmu.2019.01883","journal-title":"Front Immunol"},{"key":"10362_CR133","unstructured":"(MabThera) EAoM-I-R (2020) https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/mabthera-epar-product-information_en.pdf"},{"key":"10362_CR134","unstructured":"Administration FaD (2020) https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/103705s5367s5388lbl.pdf"},{"issue":"4","key":"10362_CR135","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s13311-017-0557-4","volume":"14","author":"JM Gelfand","year":"2017","unstructured":"Gelfand JM, Cree BAC, Hauser SL (2017) Ocrelizumab and other CD20(+) B-cell-depleting therapies in multiple sclerosis. Neurotherapeutics 14(4):835\u2013841. https:\/\/doi.org\/10.1007\/s13311-017-0557-4","journal-title":"Neurotherapeutics"},{"key":"10362_CR136","unstructured":"JR (2019) Rituximab for treatment of aggressive multiple sclerosis during pregnancy: a case study. Academy of American Neurology Annual Meeting, May 4\u201310, 2019; Philadelphia, PA Abstract P42\u2013103"},{"key":"10362_CR137","doi-asserted-by":"crossref","unstructured":"LaHue S KK, Rutatangwa A, et al (2019) Minimal concentrations of rituximab in the breastmilk of women treated for multiple sclerosis. Academy of American Neurology Annual Meeting, May 4\u201310, 2019; Philadelphia, PA Abstract P42\u2013097","DOI":"10.1212\/WNL.92.15_supplement.P4.2-097"},{"issue":"3","key":"10362_CR138","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.nrl.2020.03.001","volume":"35","author":"J Matias-Guiu","year":"2020","unstructured":"Matias-Guiu J, Gomez-Pinedo U, Montero-Escribano P, Gomez-Iglesias P, Porta-Etessam J, Matias-Guiu JA (2020) Should we expect neurological symptoms in the SARS-CoV-2 epidemic? Neurologia 35(3):170\u2013175. https:\/\/doi.org\/10.1016\/j.nrl.2020.03.001","journal-title":"Neurologia"},{"key":"10362_CR139","doi-asserted-by":"publisher","first-page":"106203","DOI":"10.1016\/j.clineuro.2020.106203","volume":"197","author":"S Salama","year":"2020","unstructured":"Salama S, Ahmed SF, Ibrahim Ismail I, Alroughani R (2020) Impact of coronavirus disease (COVID-19) pandemic on multiple sclerosis care. Clin Neurol Neurosurg 197:106203. https:\/\/doi.org\/10.1016\/j.clineuro.2020.106203","journal-title":"Clin Neurol Neurosurg"},{"key":"10362_CR140","doi-asserted-by":"publisher","DOI":"10.1111\/all.14462","author":"M Sokolowska","year":"2020","unstructured":"Sokolowska M, Lukasik Z, Agache I, Akdis CA, Akdis D, Akdis M, Barcik W, Brough H, Eiwegger T, Eliaszewicz A, Eyerich S, Feleszko W, Gomez Casado C, Hoffmann-Sommergruber K, Janda J, Jimenez-Saiz R, Jutel M, Knol E, Kortekaas Krohn I, Kothari A, Makowska J, Moniuszko M, Morita H, O\u2019Mahony L, Nadeau K, Ozdemir C, Pali-Scholl I, Palomares O, Papaleo F, Prunicki M, Schmidt-Weber CB, Sediva A, Schwarze J, Shamji MH, Tramper-Stranders G, van de Veen W, Untersmayr E (2020) Immunology of COVID-19: mechanisms, clinical outcome, diagnostics and perspectives\u2014a report of the European Academy of Allergy and Clinical Immunology (EAACI). Allergy. https:\/\/doi.org\/10.1111\/all.14462","journal-title":"Allergy"},{"key":"10362_CR141","doi-asserted-by":"publisher","first-page":"102120","DOI":"10.1016\/j.msard.2020.102120","volume":"42","author":"G Novi","year":"2020","unstructured":"Novi G, Mikulska M, Briano F, Toscanini F, Tazza F, Uccelli A, Inglese M (2020) COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role? Mult Scler Relat Disord 42:102120. https:\/\/doi.org\/10.1016\/j.msard.2020.102120","journal-title":"Mult Scler Relat Disord"},{"issue":"6","key":"10362_CR142","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/s41577-020-0311-8","volume":"20","author":"MZ Tay","year":"2020","unstructured":"Tay MZ, Poh CM, Renia L, MacAry PA, Ng LFP (2020) The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol 20(6):363\u2013374. https:\/\/doi.org\/10.1038\/s41577-020-0311-8","journal-title":"Nat Rev Immunol"},{"key":"10362_CR143","doi-asserted-by":"publisher","first-page":"102195","DOI":"10.1016\/j.msard.2020.102195","volume":"43","author":"F Safavi","year":"2020","unstructured":"Safavi F, Nourbakhsh B, Azimi AR (2020) B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran. Mult Scler Relat Disord 43:102195. https:\/\/doi.org\/10.1016\/j.msard.2020.102195","journal-title":"Mult Scler Relat Disord"},{"key":"10362_CR144","doi-asserted-by":"publisher","unstructured":"Maria Pia Sormani NDR, Irene Schiavetti Luca, Carmisciano CC, Lucia Moiola, Marta Radaelli, Paolo, Immovilli Marco Capobianco MT, Paola Zaratin, Gioacchino Tedeschi GC, Mario Alberto Battaglia, Francesco Patti MS, and the Musc-19 study group (2020) Disease modifying therapies and COVID-19 severity in multiple sclerosis. Lancet Neurol. Available at SSRN: https:\/\/doi.org\/10.2139\/ssrn.3631244","DOI":"10.2139\/ssrn.3631244"},{"key":"10362_CR145","unstructured":"Coles ALM, Giovannoni G, Anderson P, Dorsey-Campbell R, Qualie M, Vieira JJ (2020) ABN guidance on the use of disease-modifying therapies in multiple sclerosis in response to the threat of a coronavirus epidemic. https:\/\/cdn.ymaws.com\/www.theabn.org\/resource\/collection\/65C334C7-30FA-45DB-93AA-74B3A3A20293\/02.04.20_ABN_Guidance_on_DMTs_for_MS_and_COVID19_VERSION_4_April_2nd.pdf. Accessed Nov 2020"},{"issue":"2","key":"10362_CR146","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1111\/bjh.16896","volume":"190","author":"PR Tepasse","year":"2020","unstructured":"Tepasse PR, Hafezi W, Lutz M, Kuhn J, Wilms C, Wiewrodt R, Sackarnd J, Keller M, Schmidt HH, Vollenberg R (2020) Persisting SARS-CoV-2 viraemia after rituximab therapy: two cases with fatal outcome and a review of the literature. Br J Haematol 190(2):185\u2013188. https:\/\/doi.org\/10.1111\/bjh.16896","journal-title":"Br J Haematol"},{"issue":"10","key":"10362_CR147","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1177\/1352458520943791","volume":"26","author":"H Wurm","year":"2020","unstructured":"Wurm H, Attfield K, Iversen AK, Gold R, Fugger L, Haghikia A (2020) Recovery from COVID-19 in a B-cell-depleted multiple sclerosis patient. Mult Scler 26(10):1261\u20131264. https:\/\/doi.org\/10.1177\/1352458520943791","journal-title":"Mult Scler"},{"issue":"2","key":"10362_CR148","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/cei.13495","volume":"202","author":"D Baker","year":"2020","unstructured":"Baker D, Roberts CAK, Pryce G, Kang AS, Marta M, Reyes S, Schmierer K, Giovannoni G, Amor S (2020) COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases. Clin Exp Immunol 202(2):149\u2013161. https:\/\/doi.org\/10.1111\/cei.13495","journal-title":"Clin Exp Immunol"},{"key":"10362_CR149","unstructured":"ClinicalTrials.gov (2020) A study to evaluate the effects of ocrelizumab on immune responses in participants with relapsing forms of multiple sclerosis. Accessed 22 Nov 2020"},{"key":"10362_CR150","doi-asserted-by":"publisher","first-page":"102185","DOI":"10.1016\/j.msard.2020.102185","volume":"42","author":"P Montero-Escribano","year":"2020","unstructured":"Montero-Escribano P, Matias-Guiu J, Gomez-Iglesias P, Porta-Etessam J, Pytel V, Matias-Guiu JA (2020) Anti-CD20 and COVID-19 in multiple sclerosis and related disorders: A case series of 60 patients from Madrid. Spain Mult Scler Relat Disord 42:102185. https:\/\/doi.org\/10.1016\/j.msard.2020.102185","journal-title":"Spain Mult Scler Relat Disord"},{"issue":"11","key":"10362_CR151","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1080\/14656566.2019.1615880","volume":"20","author":"E D'Amico","year":"2019","unstructured":"D\u2019Amico E, Chisari CG, Gitto L, Zanghi A, Toscano S, Patti F (2019) Pharmacoeconomics of synthetic therapies for multiple sclerosis. Expert Opin Pharmacother 20(11):1331\u20131340. https:\/\/doi.org\/10.1080\/14656566.2019.1615880","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"10362_CR152","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s13317-017-0100-y","volume":"8","author":"FH Du","year":"2017","unstructured":"Du FH, Mills EA, Mao-Draayer Y (2017) Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment. Auto Immun Highlights 8(1):12. https:\/\/doi.org\/10.1007\/s13317-017-0100-y","journal-title":"Auto Immun Highlights"},{"issue":"1","key":"10362_CR153","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/228424031878428","volume":"5","author":"C Rognoni","year":"2018","unstructured":"Rognoni C, Bertolani A, Jommi C (2018) Budget impact analysis of rituximab biosimilar in Italy from the hospital and payer perspectives. Glob Reg Health Technol Assess 5(1):1\u201311. https:\/\/doi.org\/10.1177\/228424031878428","journal-title":"Glob Reg Health Technol Assess"},{"issue":"4","key":"10362_CR154","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1007\/s13311-017-0566-3","volume":"14","author":"DM Hartung","year":"2017","unstructured":"Hartung DM (2017) Economics and cost-effectiveness of multiple sclerosis therapies in the USA. Neurotherapeutics 14(4):1018\u20131026. https:\/\/doi.org\/10.1007\/s13311-017-0566-3","journal-title":"Neurotherapeutics"},{"key":"10362_CR155","unstructured":"Genenentech (2020) OCREVUS pricing and financial support https:\/\/www.ocrevus.com\/patient\/cost.html Accessed 20 Nov 2020"},{"issue":"3","key":"10362_CR156","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/nrd.2017.36","volume":"16","author":"A Mullard","year":"2017","unstructured":"Mullard A (2017) Bracing for the biosimilar wave. Nat Rev Drug Discov 16(3):152\u2013154. https:\/\/doi.org\/10.1038\/nrd.2017.36","journal-title":"Nat Rev Drug Discov"},{"key":"10362_CR157","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2147\/CEOR.S12494","volume":"3","author":"S Simoens","year":"2011","unstructured":"Simoens S (2011) Biosimilar medicines and cost-effectiveness. Clinicoecon Outcomes Res 3:29\u201336. https:\/\/doi.org\/10.2147\/CEOR.S12494","journal-title":"Clinicoecon Outcomes Res"},{"issue":"1S2","key":"10362_CR158","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1053\/sonc.2003.50033","volume":"30","author":"E Montserrat","year":"2003","unstructured":"Montserrat E (2003) Rituximab in chronic lymphocytic leukemia. Semin Oncol 30(1S2):34\u201339. https:\/\/doi.org\/10.1053\/sonc.2003.50033","journal-title":"Semin Oncol"},{"issue":"8","key":"10362_CR159","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1111\/ene.13936","volume":"26","author":"M Boremalm","year":"2019","unstructured":"Boremalm M, Juto A, Axelsson M, Novakova L, Frisell T, Svenningsson A, Lycke J, Piehl F, Salzer J (2019) Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis. Eur J Neurol 26(8):1060\u20131067. https:\/\/doi.org\/10.1111\/ene.13936","journal-title":"Eur J Neurol"},{"issue":"8","key":"10362_CR160","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1002\/art.22019","volume":"54","author":"P Roll","year":"2006","unstructured":"Roll P, Palanichamy A, Kneitz C, Dorner T, Tony HP (2006) Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum 54(8):2377\u20132386. https:\/\/doi.org\/10.1002\/art.22019","journal-title":"Arthritis Rheum"},{"issue":"20","key":"10362_CR161","doi-asserted-by":"publisher","first-page":"4834","DOI":"10.1182\/blood-2008-10-186999","volume":"113","author":"KR Carson","year":"2009","unstructured":"Carson KR, Evens AM, Richey EA, Habermann TM, Focosi D, Seymour JF, Laubach J, Bawn SD, Gordon LI, Winter JN, Furman RR, Vose JM, Zelenetz AD, Mamtani R, Raisch DW, Dorshimer GW, Rosen ST, Muro K, Gottardi-Littell NR, Talley RL, Sartor O, Green D, Major EO, Bennett CL (2009) Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 113(20):4834\u20134840. https:\/\/doi.org\/10.1182\/blood-2008-10-186999","journal-title":"Blood"},{"issue":"9","key":"10362_CR162","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1001\/archneurol.2011.103","volume":"68","author":"DB Clifford","year":"2011","unstructured":"Clifford DB, Ances B, Costello C, Rosen-Schmidt S, Andersson M, Parks D, Perry A, Yerra R, Schmidt R, Alvarez E, Tyler KL (2011) Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch Neurol 68(9):1156\u20131164. https:\/\/doi.org\/10.1001\/archneurol.2011.103","journal-title":"Arch Neurol"},{"issue":"3","key":"10362_CR163","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1177\/1352458511418631","volume":"18","author":"AS Nielsen","year":"2012","unstructured":"Nielsen AS, Miravalle A, Langer-Gould A, Cooper J, Edwards KR, Kinkel RP (2012) Maximally tolerated versus minimally effective dose: the case of rituximab in multiple sclerosis. Mult Scler 18(3):377\u2013378. https:\/\/doi.org\/10.1177\/1352458511418631","journal-title":"Mult Scler"},{"issue":"1","key":"10362_CR164","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s13311-015-0409-z","volume":"13","author":"A Shirani","year":"2016","unstructured":"Shirani A, Okuda DT, Stuve O (2016) Therapeutic advances and future prospects in progressive forms of multiple sclerosis. Neurotherapeutics 13(1):58\u201369. https:\/\/doi.org\/10.1007\/s13311-015-0409-z","journal-title":"Neurotherapeutics"},{"issue":"1\u20132","key":"10362_CR165","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.jneuroim.2014.08.617","volume":"276","author":"V Studer","year":"2014","unstructured":"Studer V, Rossi S, Motta C, Buttari F, Centonze D (2014) Peripheral B cell depletion and central proinflammatory cytokine reduction following repeated intrathecal administration of rituximab in progressive Multiple Sclerosis. J Neuroimmunol 276(1\u20132):229\u2013231. https:\/\/doi.org\/10.1016\/j.jneuroim.2014.08.617","journal-title":"J Neuroimmunol"},{"issue":"2","key":"10362_CR166","doi-asserted-by":"publisher","first-page":"e79","DOI":"10.1212\/NXI.0000000000000079","volume":"2","author":"A Svenningsson","year":"2015","unstructured":"Svenningsson A, Bergman J, Dring A, Vagberg M, Birgander R, Lindqvist T, Gilthorpe J, Bergenheim T (2015) Rapid depletion of B lymphocytes by ultra-low-dose rituximab delivered intrathecally. Neurol Neuroimmunol Neuroinflamm 2(2):e79. https:\/\/doi.org\/10.1212\/NXI.0000000000000079","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"1","key":"10362_CR167","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s00415-018-9092-4","volume":"266","author":"G Ellrichmann","year":"2019","unstructured":"Ellrichmann G, Bolz J, Peschke M, Duscha A, Hellwig K, Lee DH, Linker RA, Gold R, Haghikia A (2019) Peripheral CD19(+) B-cell counts and infusion intervals as a surrogate for long-term B-cell depleting therapy in multiple sclerosis and neuromyelitis optica\/neuromyelitis optica spectrum disorders. J Neurol 266(1):57\u201367. https:\/\/doi.org\/10.1007\/s00415-018-9092-4","journal-title":"J Neurol"},{"issue":"6","key":"10362_CR168","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1002\/mus.24063","volume":"48","author":"JS Yi","year":"2013","unstructured":"Yi JS, Decroos EC, Sanders DB, Weinhold KJ, Guptill JT (2013) Prolonged B-cell depletion in MuSK myasthenia gravis following rituximab treatment. Muscle Nerve 48(6):992\u2013993. https:\/\/doi.org\/10.1002\/mus.24063","journal-title":"Muscle Nerve"},{"issue":"1","key":"10362_CR169","doi-asserted-by":"publisher","first-page":"e0190425","DOI":"10.1371\/journal.pone.0190425","volume":"13","author":"AB Memon","year":"2018","unstructured":"Memon AB, Javed A, Caon C, Srivastawa S, Bao F, Bernitsas E, Chorostecki J, Tselis A, Seraji-Bozorgzad N, Khan O (2018) Long-term safety of rituximab induced peripheral B-cell depletion in autoimmune neurological diseases. PLoS ONE 13(1):e0190425. https:\/\/doi.org\/10.1371\/journal.pone.0190425","journal-title":"PLoS ONE"},{"issue":"11","key":"10362_CR170","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1001\/archneurol.2011.154","volume":"68","author":"SH Kim","year":"2011","unstructured":"Kim SH, Kim W, Li XF, Jung IJ, Kim HJ (2011) Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. Arch Neurol 68(11):1412\u20131420. https:\/\/doi.org\/10.1001\/archneurol.2011.154","journal-title":"Arch Neurol"},{"issue":"7","key":"10362_CR171","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1080\/10428194.2020.1788016","volume":"61","author":"W Jurczak","year":"2020","unstructured":"Jurczak W, Dlugosz-Danecka M (2020) Rituximab biosimilars in clinical practice. Leuk Lymphoma 61(7):1523\u20131524. https:\/\/doi.org\/10.1080\/10428194.2020.1788016","journal-title":"Leuk Lymphoma"},{"key":"10362_CR172","unstructured":"Initiative GaB (2020) EMA approval for rituximab biosimilar Truxima"},{"key":"10362_CR173","unstructured":"(EMA) EMA (2020) Rixathon https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/rixathon. Accessed 10 Nov 2020"},{"issue":"3","key":"10362_CR174","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1136\/annrheumdis-2016-209540","volume":"76","author":"DH Yoo","year":"2017","unstructured":"Yoo DH, Suh CH, Shim SC, Jeka S, Cons-Molina FF, Hrycaj P, Wiland P, Lee EY, Medina-Rodriguez FG, Shesternya P, Radominski S, Stanislav M, Kovalenko V, Sheen DH, Myasoutova L, Lim MJ, Choe JY, Lee SJ, Lee SY, Kwon TS, Park W (2017) A multicentre randomised controlled trial to compare the pharmacokinetics, efficacy and safety of CT-P10 and innovator rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 76(3):566\u2013570. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209540","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10362_CR175","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s40259-013-0036-3","volume":"27","author":"J Visser","year":"2013","unstructured":"Visser J, Feuerstein I, Stangler T, Schmiederer T, Fritsch C, Schiestl M (2013) Physicochemical and functional comparability between the proposed biosimilar rituximab GP2013 and originator rituximab. BioDrugs 27(5):495\u2013507. https:\/\/doi.org\/10.1007\/s40259-013-0036-3","journal-title":"BioDrugs"},{"issue":"8","key":"10362_CR176","doi-asserted-by":"publisher","first-page":"e350","DOI":"10.1016\/S2352-3026(17)30106-0","volume":"4","author":"W Jurczak","year":"2017","unstructured":"Jurczak W, Moreira I, Kanakasetty GB, Munhoz E, Echeveste MA, Giri P, Castro N, Pereira J, Akria L, Alexeev S, Osmanov E, Zhu P, Alexandrova S, Zubel A, Harlin O, Amersdorffer J (2017) Rituximab biosimilar and reference rituximab in patients with previously untreated advanced follicular lymphoma (ASSIST-FL): primary results from a confirmatory phase 3, double-blind, randomised, controlled study. Lancet Haematol 4(8):e350\u2013e361. https:\/\/doi.org\/10.1016\/S2352-3026(17)30106-0","journal-title":"Lancet Haematol"},{"issue":"9","key":"10362_CR177","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1136\/annrheumdis-2017-211281","volume":"76","author":"JS Smolen","year":"2017","unstructured":"Smolen JS, Cohen SB, Tony HP, Scheinberg M, Kivitz A, Balanescu A, Gomez-Reino J, Cen L, Zhu P, Shisha T (2017) A randomised, double-blind trial to demonstrate bioequivalence of GP2013 and reference rituximab combined with methotrexate in patients with active rheumatoid arthritis. Ann Rheum Dis 76(9):1598\u20131602. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211281","journal-title":"Ann Rheum Dis"},{"key":"10362_CR178","doi-asserted-by":"publisher","DOI":"10.1177\/1352458520912170","author":"T Perez","year":"2020","unstructured":"Perez T, Rico A, Boutiere C, Maarouf A, Roudot M, Honore S, Pelletier J, Bertault-Peres P, Audoin B (2020) Comparison of rituximab originator (MabThera((R))) to biosimilar (Truxima((R))) in patients with multiple sclerosis. Mult Scler. https:\/\/doi.org\/10.1177\/1352458520912170","journal-title":"Mult Scler"},{"issue":"1","key":"10362_CR179","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1136\/practneurol-2018-001899","volume":"19","author":"DH Whittam","year":"2019","unstructured":"Whittam DH, Tallantyre EC, Jolles S, Huda S, Moots RJ, Kim HJ, Robertson NP, Cree BAC, Jacob A (2019) Rituximab in neurological disease: principles, evidence and practice. Pract Neurol 19(1):5\u201320. https:\/\/doi.org\/10.1136\/practneurol-2018-001899","journal-title":"Pract Neurol"},{"issue":"2","key":"10362_CR180","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S1474-4422(12)70310-1","volume":"12","author":"MJ Titulaer","year":"2013","unstructured":"Titulaer MJ, McCracken L, Gabilondo I, Armangue T, Glaser C, Iizuka T, Honig LS, Benseler SM, Kawachi I, Martinez-Hernandez E, Aguilar E, Gresa-Arribas N, Ryan-Florance N, Torrents A, Saiz A, Rosenfeld MR, Balice-Gordon R, Graus F, Dalmau J (2013) Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 12(2):157\u2013165. https:\/\/doi.org\/10.1016\/S1474-4422(12)70310-1","journal-title":"Lancet Neurol"},{"issue":"3","key":"10362_CR181","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1136\/jnnp.2009.188912","volume":"82","author":"L Benedetti","year":"2011","unstructured":"Benedetti L, Briani C, Franciotta D, Fazio R, Paolasso I, Comi C, Luigetti M, Sabatelli M, Giannini F, Mancardi GL, Schenone A, Nobile-Orazio E, Cocito D (2011) Rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a report of 13 cases and review of the literature. J Neurol Neurosurg Psychiatry 82(3):306\u2013308. https:\/\/doi.org\/10.1136\/jnnp.2009.188912","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"14","key":"10362_CR182","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1212\/WNL.0000000000000293","volume":"82","author":"C Salvarani","year":"2014","unstructured":"Salvarani C, Brown RD Jr, Huston J 3rd, Morris JM, Hunder GG (2014) Treatment of primary CNS vasculitis with rituximab: case report. Neurology 82(14):1287\u20131288. https:\/\/doi.org\/10.1212\/WNL.0000000000000293","journal-title":"Neurology"},{"issue":"11","key":"10362_CR183","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1001\/jamaneurol.2016.1637","volume":"73","author":"V Damato","year":"2016","unstructured":"Damato V, Evoli A, Iorio R (2016) Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis. JAMA Neurol 73(11):1342\u20131348. https:\/\/doi.org\/10.1001\/jamaneurol.2016.1637","journal-title":"JAMA Neurol"},{"issue":"4","key":"10362_CR184","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1136\/practneurol-2012-000237","volume":"12","author":"J Palace","year":"2012","unstructured":"Palace J, Leite MI, Jacob A (2012) A practical guide to the treatment of neuromyelitis optica. Pract Neurol 12(4):209\u2013214. https:\/\/doi.org\/10.1136\/practneurol-2012-000237","journal-title":"Pract Neurol"},{"issue":"8","key":"10362_CR185","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1212\/WNL.0b013e3182a1aac7","volume":"81","author":"CS Yang","year":"2013","unstructured":"Yang CS, Yang L, Li T, Zhang DQ, Jin WN, Li MS, Su N, Zhangning N, Liu Q, Shao ZH, Yu C, Shi FD (2013) Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica. Neurology 81(8):710\u2013713. https:\/\/doi.org\/10.1212\/WNL.0b013e3182a1aac7","journal-title":"Neurology"},{"issue":"3","key":"10362_CR186","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s13760-017-0795-6","volume":"117","author":"M Zhang","year":"2017","unstructured":"Zhang M, Zhang C, Bai P, Xue H, Wang G (2017) Effectiveness of low dose of rituximab compared with azathioprine in Chinese patients with neuromyelitis optica: an over 2-year follow-up study. Acta Neurol Belg 117(3):695\u2013702. https:\/\/doi.org\/10.1007\/s13760-017-0795-6","journal-title":"Acta Neurol Belg"},{"issue":"6","key":"10362_CR187","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1136\/annrheumdis-2014-206404","volume":"74","author":"RB Jones","year":"2015","unstructured":"Jones RB, Furuta S, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, Savage CO, Segelmark M, Tesar V, van Paassen P, Walsh M, Westman K, Jayne DR, European Vasculitis S (2015) Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial. Ann Rheum Dis 74(6):1178\u20131182. https:\/\/doi.org\/10.1136\/annrheumdis-2014-206404","journal-title":"Ann Rheum Dis"},{"key":"10362_CR188","unstructured":"National Institute for Health and Care Excellence technology appraisal guidance TA308 Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis. https:\/\/www.nice.org.uk\/guidance\/ta308\/chapter\/1-Guidance. Accessed 16 Jun 2020"},{"issue":"5","key":"10362_CR189","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1007\/s00415-014-7532-3","volume":"262","author":"R Iorio","year":"2015","unstructured":"Iorio R, Damato V, Alboini PE, Evoli A (2015) Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis. J Neurol 262(5):1115\u20131119. https:\/\/doi.org\/10.1007\/s00415-014-7532-3","journal-title":"J Neurol"},{"issue":"2","key":"10362_CR190","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/mus.25597","volume":"56","author":"R Tandan","year":"2017","unstructured":"Tandan R, Hehir MK 2nd, Waheed W, Howard DB (2017) Rituximab treatment of myasthenia gravis: a systematic review. Muscle Nerve 56(2):185\u2013196. https:\/\/doi.org\/10.1002\/mus.25597","journal-title":"Muscle Nerve"},{"issue":"6","key":"10362_CR191","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1002\/ana.25770","volume":"87","author":"S Amor","year":"2020","unstructured":"Amor S, Baker D, Khoury SJ, Schmierer K, Giovanonni G (2020) SARS-CoV-2 and multiple sclerosis: not all immune depleting DMTs are equal or bad. Ann Neurol 87(6):794\u2013797. https:\/\/doi.org\/10.1002\/ana.25770","journal-title":"Ann Neurol"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-020-10362-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-020-10362-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-020-10362-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T22:35:11Z","timestamp":1744151711000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-020-10362-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,8]]},"references-count":191,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["10362"],"URL":"https:\/\/doi.org\/10.1007\/s00415-020-10362-z","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,8]]},"assertion":[{"value":"4 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Clara Grazia Chisari\u00a0received grant for congress participation from\u00a0Almiral, Biogen, Merck Serono, Novartis, Roche, Sanofi and TEVA. Eleonora Sgarlata declares no conflict of interest. Sebastiano Arena declares no conflict of interest. Simona Toscano declares no conflict of interest. Maria Luca declares no conflict of interest. Francesco Patti has received honoraria for speaking activities by Bayer Schering, Biogen, Merck Serono, Novartis and Sanofi Aventis; he also served as advisory board member the following companies: Bayer Schering, Biogen Idec, Merck Serono, Novartis; he was also funded by Pfizer and FISM for epidemiological studies; finally he received grant for congress participation from Bayer Schering, Biogen Idec, Merck Serono, Novartis, Roche, Sanofi Aventis and TEVA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}